Evidence map›Paper›PMID 35126793›Full record

ArticleDisease markers2022

A Sight of the Diagnostic Value of Aberrant Cell-Free DNA Methylation in Lung Cancer.

Hui Zhao, Hui Zhang, Wei Xu, Baiqing Wen, Yani Kang

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Disease markers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Hui ZhaoSchool of Biomedical Engineering, Bio-ID Center, Shanghai Jiao Tong University, Shanghai 200240, China.ORCID https://orcid.org/0000-0002-0872-8528
Hui ZhangDepartment of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Lung Cancer Center, Shanghai Jiao Tong University, Shanghai 200030, China.ORCID https://orcid.org/0000-0001-5784-3111
Wei XuSchool of Biomedical Engineering, Bio-ID Center, Shanghai Jiao Tong University, Shanghai 200240, China.ORCID https://orcid.org/0000-0003-4223-6508
Baiqing WenSchool of Biomedical Engineering, Bio-ID Center, Shanghai Jiao Tong University, Shanghai 200240, China.ORCID https://orcid.org/0000-0003-4135-1651
Yani KangSchool of Biomedical Engineering, Bio-ID Center, Shanghai Jiao Tong University, Shanghai 200240, China.ORCID https://orcid.org/0000-0002-6753-386X
Shanghai Jiao Tong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLung cancer is one of the most commonly diagnosed cancer worldwide. As one of the liquid biopsy analytes, alternations in cell-free DNA (cfDNA) methylation could function as promising biomarkers for lung cancer detection.

methodsIn this study, differential methylation analysis was performed to identify candidate markers, and lasso regression with 10-fold cross-validation (CV) was used to establish the diagnostic marker panel. The performance of the binary classifier was evaluated using the receiver operating characteristic (ROC) curve and the precision-recall (PR) curve.

resultsWe identified 4072 differentially methylated regions (DMRs) based on cfDNA methylation data, and then a 10-DMR marker panel was established. The panel achieved an area under the ROC curve (AUROC) of 0.922 and an area under the PR curve (AUPR) of 0.899 in a cfDNA cohort containing 29 lung cancer and 74 normal samples, showing outstanding performance. Besides, the cfDNA-derived markers also performed well in primary tissue datasets, which were more robust than the tissue-derived markers.

conclusionOur study suggested that the 10-DMR marker panel attained high accuracy and robustness and may function as a novel and promising target for lung cancer detection.

Indexed as

Biomarkers, TumorDNA MethylationCell-Free Nucleic AcidsHumansLung NeoplasmsPredictive Value of TestsBiomarkers, TumorCell-Free Nucleic Acids

Identifiers

PMID35126793
PMCPMC8814721
OpenAlexW4210674017

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.